2020
A Mission Begins
Britecyte is founded with a simple belief: the future of medicine isn't about replacing what's missing—it's about restoring what has been lost.
Restore What's Yours™
At Britecyte, we believe the future of medicine isn't about simply replacing what's missing—it's about restoring what's yours.
Whether that means restoring structure, function, or quality of life, we develop innovative therapies designed to help people regain what has been lost. We call this approach Biorestoration—working with the body's natural biology to restore, rather than replace.
By advancing therapies that work with the body's natural biology, we aim to move beyond symptom management toward solutions designed to repair, rebuild, and restore.
Building the Future of
Biorestoration.
- 60+years of experience in regenerative medicine
- 20+therapies developed and launched
- 55+clinical trials conducted
- 215+patents and patent applications
- 80+peer-reviewed publications
2020
2022
Turning Vision into Innovation
Building on that mission, Britecyte develops its proprietary adipose tissue technology platform, opening new possibilities for restoring structure and function across a broad range of clinical applications.
The Maryland Stem Cell Research Fund (MSCRF) awards Britecyte a grant supporting development of a therapy for liver fibrosis.
2023
From Research to Patients
Liposana® becomes Britecyte's first commercial product, helping restore cushioning and protection to the underlying structures of the foot for patients with fat pad loss and other soft tissue deficiencies that cause pain and chronic ulceration.
2024
Expanding into Aesthetics
Building on the same platform technology, Lipoderma® is introduced to naturally restore the structural tissue beneath the skin that helps maintain the face's soft, natural contours and youthful appearance.
2025
Continuing to Advance
Clinical research expands with FDA Investigational New Drug (IND) clearance and the launch of a MSCRF-supported osteoarthritis clinical trial.
2026
Platform Technology Patented
Britecyte reaches another milestone as the U.S. Patent and Trademark Office (USPTO) awards its first two patents covering the company's adipose tissue platform technology.
Our Pipeline
Britecyte is advancing a pipeline of innovative therapies designed to restore structure and function across multiple clinical applications. Guided by decades of experience, our platform continues to expand into areas of significant unmet clinical need.
Restoring Structure
Restoring Function
A Breakthrough in Adipose Science.
A new era of adipose restoration begins with technology that makes native adipose tissue available when and where it's needed.
-
Native Structure & Function Preserved
Britecyte's proprietary processing technology preserves the native architecture of adipose tissue, including intact adipocytes and extracellular matrix, maintaining the structural and functional characteristics that make adipose tissue unique.
-
Immunogenic Components Removed
The technology selectively removes immunogenic components that have historically limited adipose tissue to autologous use, enabling allogeneic transplantation while preserving native tissue architecture.
-
Ready When You Need It
Unlike fresh autologous fat, our technology allows for convenient storage and immediate clinical use. Stable refrigerated storage (0–10°C) simplifies logistics while providing an off-the-shelf solution when patients need treatment.
-
Designed for Minimally Invasive Delivery
The preserved tissue is formulated for minimally invasive implantation using standard cannulas or needles, allowing physicians to restore lost structure through a familiar clinical workflow.
Meet the team.
Samson Tom, PhD, MBA President and CEO, Co-Founder
Alla Danilkovitch, PhD Founder and Chief Scientific Officer
Molly Saunders VP, Customer Engagement
Lisa Rodemann Director, Customer Experience
Peter Friedli Chairman and Co-Founder
Dr. Tom became President and CEO of Britecyte in June 2022. He brings more than 25 years of experience developing and commercializing advanced biologics, devices, and tissue-based products—including as President and CEO of Osiris Therapeutics through its acquisition by Smith+Nephew.
Dr. Danilkovitch founded Britecyte in 2020 and leads its scientific vision in regenerative medicine. At Osiris Therapeutics she helped develop Prochymal®, BIO4™, Cartiform®, Grafix®, and Stravix™—with 30+ years of experience, 55 patents, and 60 publications across academia, government, and industry.
Molly Saunders joined Britecyte in January 2024. Previously Senior Manager of Clinical Operations at Osiris Therapeutics, she managed multi-center tissue-based studies and co-authored publications supporting market access and reimbursement before consulting in life sciences at Alvarez & Marsal.
Lisa Rodemann joined Britecyte in January 2026. She spent 25 years at Osiris Therapeutics and Smith+Nephew across Human Resources, Clinical Programs, Marketing, and project management—including Advanced Wound Care and white-glove support for key accounts during the pandemic.
Peter Friedli has led Swiss venture capital firm Friedli Corporate Finance AG since 1986, investing in more than 170 high-tech and biotechnology companies. He co-founded and chaired Osiris Therapeutics and was its major shareholder.
